These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 7117357)

  • 1. Hepatic blood flow and drug metabolism in patients on enzyme-inducing anticonvulsants.
    Pirttiaho HI; Sotaniemi EA; Pelkonen RO; Pitkänen U
    Eur J Clin Pharmacol; 1982; 22(5):441-5. PubMed ID: 7117357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver size and indices of drug metabolism in epileptics.
    Pirttiaho HI; Sotaniemi EA; Ahokas JT; Pitkänen U
    Br J Clin Pharmacol; 1978 Sep; 6(3):273-8. PubMed ID: 687506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug metabolism in epileptics: in vivo and in vitro correlations.
    Sotaniemi EA; Pelkonen RO; Ahokas J; Pirttiaho HI; Ahlqvist J
    Br J Clin Pharmacol; 1978 Jan; 5(1):71-6. PubMed ID: 619937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow.
    Branch RA; Shand DG; Wilkinson GR; Nies AS
    J Clin Invest; 1974 Apr; 53(4):1101-7. PubMed ID: 4205524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver size and indices of drug metabolism in alcoholics.
    Pirttiaho HI; Sotaniemi EA; Ahlqvist J; Pitkänen U; Pelkonen RO
    Eur J Clin Pharmacol; 1978 Mar; 13(1):61-7. PubMed ID: 639835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug metabolism in diabetic subjects with fatty livers.
    Pirttiaho HI; Salmela PI; Sotaniemi EA; Pelkonen RO; Pitkänen U; Luoma PV
    Br J Clin Pharmacol; 1984 Dec; 18(6):895-9. PubMed ID: 6529530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between lipid composition and drug metabolizing capacity of human liver.
    Savolainen MJ; Arranto AJ; Hassinen IE; Luoma PV; Pelkonen RO; Sotaniemi EA
    Eur J Clin Pharmacol; 1985; 27(6):727-32. PubMed ID: 3987778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roles of hepatic blood flow and enzyme activity in the kinetics of propranolol and sotalol.
    Pirttiaho HI; Sotaniemi EA; Pelkonen RO; Pitkänen U; Anttila M; Sundqvist H
    Br J Clin Pharmacol; 1980 Apr; 9(4):399-405. PubMed ID: 7378257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver size in evaluating drug metabolizing capacity in man.
    Pirttiaho H
    Int J Clin Pharmacol Biopharm; 1979 Jun; 17(6):271-6. PubMed ID: 468452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of histamine H2-receptor antagonists on the hepatic elimination of drugs].
    Klotz U; Reimann I
    Klin Wochenschr; 1983 Jul; 61(13):625-32. PubMed ID: 6136626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers.
    Bartoli A; Gatti G; Cipolla G; Barzaghi N; Veliz G; Fattore C; Mumford J; Perucca E
    Epilepsia; 1997 Jun; 38(6):702-7. PubMed ID: 9186253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salivary antipyrine kinetics in hepatic and renal disease and in patients on anticonvulsant therapy.
    Harman AW; Penhall RK; Priestly BG; Frewin DB; Phillips PJ; Clarkson AR
    Aust N Z J Med; 1977 Aug; 7(4):385-90. PubMed ID: 270989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis.
    Bauer LA; O'Sullivan T; Reiss WG; Horn JR; Opheim K; Strandness DE; Carithers RL
    Br J Clin Pharmacol; 1994 Apr; 37(4):375-81. PubMed ID: 8018459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients.
    Perucca E; Hedges A; Makki KA; Ruprah M; Wilson JF; Richens A
    Br J Clin Pharmacol; 1984 Sep; 18(3):401-10. PubMed ID: 6435654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic injury and drug metabolism in patients with alpha-methyldopa-induced liver damage.
    Sotaniemi EA; Hokkanen OT; Ahokas JT; Pelkonen RO; Ahlqvist J
    Eur J Clin Pharmacol; 1977 Dec; 12(6):429-35. PubMed ID: 598417
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of nifedipine on hepatic drug oxidation.
    Dickinson TH; Egan JM; Abernethy DR
    Pharmacology; 1988; 36(6):405-10. PubMed ID: 3420161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug metabolism in man: in vivo and in vitro correlations.
    Sotaniemi EA; Pelkonen RO; Ahokas J; Ahlqvist J; Hokkanen OT
    Arch Toxicol Suppl; 1978; (1):339-42. PubMed ID: 277127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum LDL cholesterol, the LDL/HDL cholesterol ratio and liver microsomal enzyme induction evaluated by antipyrine kinetics.
    Luoma PV; Sotaniemi EA; Arranto AJ
    Scand J Clin Lab Invest; 1983 Dec; 43(8):671-5. PubMed ID: 6665516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug metabolism in liver disease: activity of hepatic microsomal metabolizing enzymes.
    Farrell GC; Cooksley WG; Powell LW
    Clin Pharmacol Ther; 1979 Oct; 26(4):483-92. PubMed ID: 487696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma clearance of propranolol and sotalol and hepatic drug-metabolizing enzyme activity.
    Sotaniemi EA; Anttila M; Pelkonen RO; Järvensivu P; Sundquist H
    Clin Pharmacol Ther; 1979 Aug; 26(2):153-61. PubMed ID: 455885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.